89bio, Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 31.89. In total, the insiders bought 8 717 496 and sold 3 336 793 ETNB shares in the last 100 trades.

Insider Power

(Last 100 transactions)
31.89
Buy 8 717 496 Shares
Sell 3 336 793 Shares

Historical Insider Trades

Date Type Action Person Amount
May 02, 2024 Stock Option (Right to Buy) Buy Babler Martin 67 700
Apr 13, 2024 Buy Babler Martin 0
Apr 11, 2024 Common Stock Buy Ra Capital Management, L.p. 1 408 450
Apr 11, 2024 Warrants (Right to Buy) Sell Ra Capital Management, L.p. 2 816 900
Apr 01, 2024 Common Stock Buy Palekar Rohan 25 000
Apr 01, 2024 Common Stock Sell Palekar Rohan 52 718
Apr 01, 2024 Stock Option (Right to Buy) Sell Palekar Rohan 25 000
Mar 04, 2024 Common Stock Buy Ra Capital Management, L.p. 1 350 000
Feb 26, 2024 Common Stock Sell Palekar Rohan 4 477
Feb 17, 2024 Common Stock Sell Martins Ryan 778
Feb 17, 2024 Common Stock Sell Palekar Rohan 4 602
Feb 17, 2024 Common Stock Sell Le-nguyen Quoc 1 046
Feb 17, 2024 Common Stock Sell Mansbach Harry H 1 046
Feb 09, 2024 Common Stock Sell Martins Ryan 3 568
Feb 09, 2024 Common Stock Sell Mansbach Harry H 3 568
Feb 09, 2024 Common Stock Sell Le-nguyen Quoc 3 568
Feb 09, 2024 Common Stock Sell Palekar Rohan 12 670
Feb 05, 2024 Common Stock Sell Mansbach Harry H 1 190
Feb 05, 2024 Common Stock Sell Le-nguyen Quoc 1 190
Feb 05, 2024 Common Stock Sell Palekar Rohan 5 068
Feb 05, 2024 Common Stock Sell Martins Ryan 892
Feb 01, 2024 Stock Option (Right to Buy) Buy Ra Capital Management, L.p. 45 150
Feb 01, 2024 Stock Option (Right to Buy) Buy Mansbach Harry H 195 000
Feb 01, 2024 Common Stock Buy Mansbach Harry H 48 750
Feb 01, 2024 Common Stock Buy Le-nguyen Quoc 48 750
Click to get the best stock tips daily for free!

About 89bio, Inc.

89bio. 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorpor... ETNB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT